A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation... -н Plummer, R, Lorigan, P, Steven, N, Scott, L, Middleton, M, Wilson, R, Mulligan, E, Curtin, N, Wang, D, Dewji, R, Abbattista, A, Gallo, J, Calvert, H

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules... -н Boss, D, Schwartz, G, Middleton, MR, Amakye, D, Swaisland, H, Midgley, R, Ranson, M, Danson, S, Calvert, H, Plummer, R, Morris, C, Carvajal, R, Chirieac, L, Schellens, J, Shapiro, G

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. -н Plummer, R, Jones, C, Middleton, M, Wilson, R, Evans, J, Olsen, A, Curtin, N, Boddy, A, McHugh, P, Newell, D, Harris, A, Johnson, P, Steinfeldt, H, Dewji, R, Wang, D, Robson, L, Calvert, H

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. -н Seymour, L, Ferry, DR, Kerr, D, Rea, D, Whitlock, M, Poyner, R, Boivin, C, Hesslewood, S, Twelves, C, Blackie, R, Schatzlein, A, Jodrell, D, Bissett, D, Calvert, H, Lind, M, Robbins, A, Burtles, S, Duncan, R, Cassidy, J